Dyne Therapeutics (NASDAQ:DYN) Trading 7% Higher – Should You Buy?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares traded up 7% on Wednesday . The company traded as high as $19.39 and last traded at $19.3330. 114,684 shares changed hands during trading, a decline of 94% from the average session volume of 1,923,842 shares. The stock had previously closed at $18.07.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Chardan Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 9th. Morgan Stanley cut their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Evercore set a $33.00 price target on Dyne Therapeutics in a research note on Friday, May 15th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Dyne Therapeutics Trading Up 11.9%

The company has a fifty day moving average of $18.25 and a two-hundred day moving average of $18.12. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $3.34 billion, a price-to-earnings ratio of -6.27 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period last year, the business earned ($1.05) earnings per share. On average, research analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In related news, CFO Erick Lucera sold 1,448 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $26,585.28. Following the completion of the sale, the chief financial officer directly owned 123,925 shares in the company, valued at approximately $2,275,263. The trade was a 1.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason P. Rhodes sold 83,219 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total value of $1,512,921.42. Following the completion of the sale, the director owned 7,962 shares of the company’s stock, valued at approximately $144,749.16. This trade represents a 91.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders acquired 9,000 shares of company stock worth $156,800 and sold 1,559,462 shares worth $29,814,746. Company insiders own 9.46% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DYN. Hilton Head Capital Partners LLC bought a new position in Dyne Therapeutics in the 1st quarter worth approximately $26,000. Strs Ohio bought a new position in Dyne Therapeutics in the 4th quarter worth approximately $51,000. Aster Capital Management DIFC Ltd bought a new position in Dyne Therapeutics in the 4th quarter worth approximately $84,000. Steward Partners Investment Advisory LLC increased its position in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares during the period. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.